Cotylenin A and arsenic trioxide cooperatively suppress cell proliferation and cell invasion activity in human breast cancer cells

Kasukabe,Takashi; Okabe-Kado,Junko; Kato,Nobuo; Honma,Yoshio; Kumakura,Shunichi

doi:10.3892/ijo.2014.2760

Cotylenin A and arsenic trioxide cooperatively suppress cell proliferation and cell invasion activity in human breast cancer cells

Authors:
- Takashi Kasukabe
- Junko Okabe-Kado
- Nobuo Kato
- Yoshio Honma
- Shunichi Kumakura
View Affiliations

Affiliations: Department of Medical Education and Research, Faculty of Medicine, Shimane University, Izumo 693-8501, Japan, Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama 362-0806, Japan, Institute of Scientific and Industrial Research, Osaka University, Osaka 567-0047, Japan, Cancer Center, Faculty of Medicine, Shimane University, Izumo 693-8501, Japan
Published online on: November 18, 2014 https://doi.org/10.3892/ijo.2014.2760
Pages: 841-848

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Arsenic trioxide (ATO) is an approved treatment for acute promyelocytic leukemia (APL). It has also shown potential for treatment of multiple myeloma and various solid tumors including breast cancer. The requirement of high, toxic concentrations for the induction of apoptosis in non-APL and solid tumor cells is a major limitation for its use in other hematological malignancies and solid tumors. We have examined whether inducers of differentiation of leukemia cells can control the growth of solid tumor cells. In the present study, we found that cotylenin A, a plant growth regulator and a potent inducer of differentiation in myeloid leukemia cells, significantly potentiated both ATO-induced inhibition of cell growth in a liquid culture, and ATO-induced inhibition of anchorage-independent growth in a semi-solid culture in human breast cancer MCF-7 and MDA-MB-231 cells. ISIR-005 (a synthetic cotylenin A-derivative) was also able to enhance ATO-induced growth inhibition. The combined treatment with cotylenin A and ATO induced cleaved caspase-7 in MCF-7 cells at the concentrations which ATO alone scarcely induced and cotylenin A alone only weakly induced. Expression of survivin in MCF-7 cells was markedly decreased with the presence of both cotylenin A and ATO, although the expression of survivin was only slightly decreased by cotylenin A or ATO alone. The pretreatment with N-acetylcysteine significantly reduced the combination treatment-induced cell growth inhibition. These data suggest that induction of cleaved caspase-7, inhibition of survivin and oxidative responses are important events in the corporative inhibition in the growth of MCF-7 cells induced by both cotylenin A and ATO. Furthermore, we found that the combined treatment with cotylenin A and ATO also could be effective in suppressing the invasive capacity of MDA-MB‑231 cells determined with the impedance-based xCELLigence Real-Time Cell Analysis technology. These results suggest that cotylenin A is an attractive enhancer for the ATO-induced anticancer activities in human breast cancer.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Naishadham MA and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
3	Hurvitz S, Hu Y, O’Brien N and Finn RS: Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev. 39:219–229. 2013. View Article : Google Scholar
4	Gianni M, Koken MH, Chelbi-Alix MK, Benoit G, et al: Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood. 91:4300–4310. 1998.PubMed/NCBI
5	Shen ZX, Chen GQ, Ni XS, et al: Use of arsenic trioxide (As₂O₃) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 89:3354–3360. 1997.PubMed/NCBI
6	Deuer D and Tallman MS: Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol. 23:2396–2410. 2005. View Article : Google Scholar
7	Platanias L: Biological responses to arsenic compounds. J Biol Chem. 284:18583–18587. 2009. View Article : Google Scholar : PubMed/NCBI
8	Emadi A and Gore SD: Arsenic trioxide-An old drug rediscovered. Blood Rev. 24:191–199. 2010. View Article : Google Scholar : PubMed/NCBI
9	Takahashi S: Combination therapy with arsenic trioxide for hematological malignancies. Anticancer Agents Med Chem. 10:504–510. 2010. View Article : Google Scholar : PubMed/NCBI
10	Zhang X, Su Y and Sun Z: Opposite effects of arsenic trioxide on the Nrf2 pathway in oral squamous cell carcinoma in vitro and in vivo. Cancer Lett. 18:93–98. 2012. View Article : Google Scholar
11	Kryeziu K, Jungwirth U, Hoda MA, et al: Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair. Mol Cancer Ther. 12:1073–1084. 2013. View Article : Google Scholar : PubMed/NCBI
12	Liu W, Gong Y, Li H, et al: Arsenic-induced growth arrest of breast cancer MCF-7 cells involving FOXO3a and IkB kinase β expression and localization. Cancer Biother Radiopharm. 27:504–512. 2012. View Article : Google Scholar : PubMed/NCBI
13	Kasukabe T, Okabe-Kado J, Haranosono Y, Kato N and Honma Y: Inhibition of rapamycin-induced Akt phosphorylation by cotylenin A correlated with their synergistic growth inhibition of cancer cells. Int J Oncol. 42:767–775. 2013.
14	Vuky J, Yu R, Schwartz L and Motzer RJ: Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Invest New Drugs. 20:327–330. 2002. View Article : Google Scholar : PubMed/NCBI
15	Kim KB, Bedikian AY, Camacho LH, Papadopoulos NE and McCullough C: A phase II trial of arsenic trioxide in patients with metastatic melanoma. Cancer. 104:1687–1692. 2005. View Article : Google Scholar : PubMed/NCBI
16	Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL and Yang CH: Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Invest New Drugs. 25:77–84. 2006. View Article : Google Scholar : PubMed/NCBI
17	Abe O, Abe R, Enomoto K, et al: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 365:1687–1717. 2005. View Article : Google Scholar
18	Zhao XY, Yang S, Chen YR, Li PC, Dou MM and Zhang J: Resveratrol and arsenic trioxide act synergistically to kill tumor cells in vitro and in vivo. PloS One. 9:e989252014. View Article : Google Scholar : PubMed/NCBI
19	Sassa T, Tojyo T and Munakata K: Isolation of a new plant growth substance with cytokinin-like activity. Nature. 227:3791970. View Article : Google Scholar : PubMed/NCBI
20	Asahi K, Honma Y and Hazeki K: Cotylenin A, a plant-growth regulator, induces the differentiation in murine and human myeloid leukemia cells. Biochem Biophys Res Commun. 238:758–763. 1997. View Article : Google Scholar : PubMed/NCBI
21	Yamamoto-Yamaguchi Y, Yamada K, Ishii Y, Asahi KI, Tomoyasu S and Honma Y: Induction of the monocytic differentiation of myeloid leukemia cells by cotylenin A, a plant growth regulator. Br J Haematol. 112:697–705. 2001. View Article : Google Scholar : PubMed/NCBI
22	Yamada K, Honma Y, Asahi KI, Sassa T, Hino KI and Tomoyasu S: Differentiation of human acute myeloid leukemia cells in primary culture in response to cotylenin A, a plant growth regulator. Br J Haematol. 114:814–821. 2001. View Article : Google Scholar : PubMed/NCBI
23	Honma Y: Cotylenin A: a plant growth regulator as a differentiation-inducing agent against myeloid leukemia. Leuk Lymphoma. 43:1169–1178. 2002. View Article : Google Scholar : PubMed/NCBI
24	Yamamoto-Yamaguchi Y, Okabe-Kado J, Kasukabe T and Honma Y: Induction of differentiation of human myeloid leukemia cells by immunosuppressant macrolides (rapamycin and FK506) and calcium/calmodulin-dependent kinase inhibitors. Exp Hematol. 29:582–588. 2001. View Article : Google Scholar : PubMed/NCBI
25	Kasukabe T, Okabe-Kado J, Kato N, Sassa T and Honma Y: Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts. Breast Cancer Res. 7:R1097–R1110. 2005. View Article : Google Scholar
26	Kasukabe T, Okabe-Kado J and Honma Y: Cotylenin A, a new differentiation inducer, and rapamycin cooperatively inhibit growth of cancer cells through induction of cyclin G2. Cancer Sci. 99:1693–1698. 2008. View Article : Google Scholar : PubMed/NCBI
27	Kawakami K, Hattori M, Inoue T, et al: A novel Fusicoccin derivative preferentially targets hypoxic tumor cells and inhibits tumor growth in xenografts. Anticancer Agents Med Chem. 12:791–800. 2012. View Article : Google Scholar : PubMed/NCBI
28	Nakamaki T, Okabe-Kado J, Yamamoto-Yamaguchi Y, et al: Role of MmTRA1b/phospholipid scramblase 1 gene expression in the induction of differentiation of human myeloid leukemia cells into granulocytes. Exp Hematol. 30:421–429. 2002. View Article : Google Scholar : PubMed/NCBI
29	Hagiwara Y, Kasukabe T, Kaneko Y, Niitsu N and Okabe-Kado J: Ellagic acid a natural compound, induces apoptosis and potentiates retinoic acid-induced differentiation of human leukemia HL-60 cells. Int J Hematol. 92:136–143. 2010. View Article : Google Scholar : PubMed/NCBI
30	Zhou C, Boggess J, Bae-Jump V and Gehrig PA: Induction of apoptosis and inhibition of telomerase activity by arsenic trioxide (As₂O₃) in endometrial carcinoma cells. Gynecol Oncol. 105:218–222. 2007. View Article : Google Scholar : PubMed/NCBI
31	Kumar P, Gao Q, Ning Y, Wang Z, Krebsbach PH and Polverini PJ: Mol Cancer Ther. 7:2060–2069. 2008. View Article : Google Scholar : PubMed/NCBI
32	Feng Y, Pan TC, Pant DK, et al: SPSB1 promotes breast cancer recurrence by potentiating c-MET signaling. Cancer Discov. 4:790–803. 2014. View Article : Google Scholar : PubMed/NCBI
33	Janicke RU, Sprenger ML, Wati MR and Porter AG: Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem. 273:9357–9360. 1998. View Article : Google Scholar : PubMed/NCBI
34	Aziz MY, Omar AR, Subramani T, et al: Damnacanthal is a potent inducer of apoptosis with anticancer activity by stimulating p53 and p21 genes in MCF-7 breast cancer cells. Oncol Lett. 7:1479–1484. 2014.PubMed/NCBI
35	Shin S, Sung BJ, Cho YS, et al: An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry. 40:1117–1123. 2001. View Article : Google Scholar : PubMed/NCBI
36	Nakahara T, Takeuchi M, Kinoyama I, et al: YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 67:8014–8021. 2007. View Article : Google Scholar : PubMed/NCBI
37	Li W, Wang M, Wang L, Ji S, Zhang J and Zhang C: Icariin synergizes with arsenic trioxide to suppress human hepatocellular carcinoma. Cell Biochem Biophys. 68:427–436. 2014. View Article : Google Scholar
38	Nakaoka T, Ota A, Ono T, et al: Combined arsenic trioxidecisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells. Cell Oncol. 37:119–129. 2014. View Article : Google Scholar
39	Limame R, Wouters A, Pauwels B, et al: Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays. PloS One. 7:e465362012. View Article : Google Scholar : PubMed/NCBI
40	Si L, Jiang F, Li Y, et al: Induction of the mesenchymal to epithelial transition by demethylation-activated microRNA-200c is involved in the anti-migration/invasion effects of arsenic trioxide on human breast cancer cells. Mol Carcinog. Apr 14–2014. View Article : Google Scholar : (Epub ahead of print).